{"id":"atazanavir-ritonavir-tenofovir-nucleoside","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hyperbilirubinemia"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Renal dysfunction (tenofovir-related)"},{"rate":"5-10","effect":"Nephrolithiasis"}]},"_chembl":{"chemblId":"CHEMBL1200678","moleculeType":"Small molecule","molecularWeight":"802.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir is a protease inhibitor that blocks HIV protease, preventing the maturation of viral particles. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing atazanavir levels. Tenofovir and the nucleoside reverse transcriptase inhibitor block reverse transcriptase, preventing viral RNA conversion to DNA and integration into host cells.","oneSentence":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication in HIV-infected patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:50.558Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT01602822","phase":"PHASE4","title":"Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV","status":"TERMINATED","sponsor":"Kenneth H. Mayer, MD","startDate":"2012-02","conditions":"HIV","enrollment":11},{"nctId":"NCT02652793","phase":"NA","title":"Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2015-11","conditions":"Human Immunodeficiency Virus","enrollment":31},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT01620944","phase":"PHASE3","title":"Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07-31","conditions":"HIV","enrollment":3},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT04022967","phase":"PHASE3","title":"ANRS 12372 MODERATO Study","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-21","conditions":"HIV-1-infection","enrollment":480},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT04385719","phase":"PHASE2","title":"Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy","status":"COMPLETED","sponsor":"Makerere University","startDate":"2021-05-05","conditions":"Ebola, HIV/AIDS","enrollment":24},{"nctId":"NCT01815736","phase":"PHASE3","title":"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":1443},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02652624","phase":"PHASE3","title":"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-02-19","conditions":"HIV-1 Infection","enrollment":472},{"nctId":"NCT01803074","phase":"PHASE2","title":"Study to Evaluate a HIV Drug for the Treatment of HIV Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-04-04","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":107},{"nctId":"NCT00335322","phase":"PHASE4","title":"ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2007-02","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":329},{"nctId":"NCT01705574","phase":"PHASE3","title":"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10-24","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":583},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01902186","phase":"PHASE4","title":"Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir","status":"TERMINATED","sponsor":"Giovanni Di Perri","startDate":"2014-09","conditions":"HIV Infection, Osteopenia","enrollment":4},{"nctId":"NCT00118898","phase":"PHASE3","title":"Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-09","conditions":"HIV Infections","enrollment":1864},{"nctId":"NCT01351740","phase":"PHASE4","title":"Switch to Unboosted Atazanavir With Tenofovir Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-07","conditions":"HIV Infection","enrollment":50},{"nctId":"NCT01903031","phase":"PHASE2","title":"Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-12-30","conditions":"HIV-1 Infection","enrollment":84},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT01003990","phase":"PHASE3","title":"Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-10","conditions":"HIV","enrollment":710},{"nctId":"NCT01829802","phase":"PHASE4","title":"RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients","status":"UNKNOWN","sponsor":"Pedro Cahn","startDate":"2014-05","conditions":"Chronic Infection With HIV","enrollment":50},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT01108510","phase":"PHASE3","title":"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-04","conditions":"HIV, HIV Infections","enrollment":698},{"nctId":"NCT01363011","phase":"PHASE3","title":"Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-05","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":106},{"nctId":"NCT00892437","phase":"PHASE2","title":"Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-05","conditions":"HIV-1 Infection","enrollment":85},{"nctId":"NCT02157311","phase":"PHASE3","title":"4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-07","conditions":"HIV-1 Infection","enrollment":100},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01637259","phase":"PHASE4","title":"MARCH Renal Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Proteinuria, HIV","enrollment":76},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334},{"nctId":"NCT00757783","phase":"PHASE4","title":"Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2008-10","conditions":"HIV","enrollment":68},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01106586","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-04","conditions":"HIV, HIV Infections","enrollment":708},{"nctId":"NCT02404259","phase":"NA","title":"PK TDF in Thai HIV-infected Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-06","conditions":"HIV","enrollment":32},{"nctId":"NCT00544128","phase":"PHASE4","title":"Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment","status":"COMPLETED","sponsor":"International Medical Center of Japan","startDate":"2007-10","conditions":"HIV Infections","enrollment":109},{"nctId":"NCT01332227","phase":"PHASE4","title":"Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"HIV, Combination Therapy","enrollment":132},{"nctId":"NCT00551018","phase":"PHASE2","title":"Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"HIV Infections","enrollment":218},{"nctId":"NCT00762892","phase":"PHASE4","title":"Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2009-01","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT01274780","phase":"PHASE4","title":"Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2011-05","conditions":"HIV-1","enrollment":180},{"nctId":"NCT01180075","phase":"","title":"Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-05","conditions":"Human Immunodeficiency Virus","enrollment":85},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00811954","phase":"PHASE3","title":"Comparative Study of Three NNRTI-Sparing HAART Regimens","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-05","conditions":"HIV Infection","enrollment":1814},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00552240","phase":"PHASE4","title":"Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"HIV Infections","enrollment":154},{"nctId":"NCT01102972","phase":"PHASE4","title":"A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-04","conditions":"Infection, Human Immunodeficiency Virus","enrollment":297},{"nctId":"NCT00896051","phase":"PHASE2","title":"TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2009-08","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":50},{"nctId":"NCT00869960","phase":"PHASE4","title":"Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2009-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT01394133","phase":"","title":"Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2011-07","conditions":"HIV Infected","enrollment":""},{"nctId":"NCT00532168","phase":"PHASE4","title":"Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2007-09","conditions":"HIV Infections","enrollment":108},{"nctId":"NCT00966329","phase":"PHASE4","title":"Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-10","conditions":"HIV, HIV Infections","enrollment":30},{"nctId":"NCT00224445","phase":"PHASE4","title":"Boosted Atazanavir and Truvada Given Once-Daily - BATON Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2005-09","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01232127","phase":"PHASE4","title":"Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-02","conditions":"HIV","enrollment":25},{"nctId":"NCT00225017","phase":"PHASE3","title":"Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-06","conditions":"HIV Infection, Hyperlipidemia","enrollment":50},{"nctId":"NCT00827112","phase":"PHASE2","title":"A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-03","conditions":"Human Immunodeficiency Virus-1","enrollment":129},{"nctId":"NCT00820118","phase":"PHASE2","title":"Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-05","conditions":"HIV Infections","enrollment":45},{"nctId":"NCT00768989","phase":"PHASE2","title":"Phase IIB Pilot of Atazanavir + Raltegravir","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2008-11","conditions":"HIV","enrollment":167},{"nctId":"NCT00528060","phase":"PHASE2","title":"Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2008-01","conditions":"HIV Infections","enrollment":35},{"nctId":"NCT00035932","phase":"PHASE3","title":"Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-11","conditions":"HIV Infections","enrollment":571}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BMS-232632","Reyataz"],"phase":"phase_3","status":"active","brandName":"Atazanavir + ritonavir + tenofovir + nucleoside","genericName":"Atazanavir + ritonavir + tenofovir + nucleoside","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication in HIV-infected patients. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}